logo
Contributor: Slashing NIH research guarantees a less healthy, less wealthy America

Contributor: Slashing NIH research guarantees a less healthy, less wealthy America

Yahoo28-05-2025
In recent months, funding for biomedical research from the National Institutes of Health has been canceled, delayed and plunged into uncertainty. According to an April STAT News analysis, NIH funding has decreased by at least $2.3 billion since the beginning of the year. KFF Health News reports the full or partial termination of approximately 780 NIH grants between Feb. 28 and March 28 alone. Additional NIH funding cuts loom on the horizon, including proposed cuts to indirect costs.
Amid this volatility, one thing remains clear: NIH grant funding is a valuable, proven investment, economically and in terms of improving human health.
A recent United for Medical Research report shows that in fiscal year 2024, research funded by the NIH generated $94.58 billion in economic activity nationwide, a 156% return on investment. Further, the report shows that NIH funding supported 407,782 jobs nationwide. According to the NIH's own figures, patents derived from work it has funded produce 20% more economic value than other U.S. patents.
These economic returns — including a return on investment that would thrill any startup or stock investor — cannot begin to capture the impact on individuals, families and communities in terms of increased longevity and higher quality of life.
While it is hard to precisely quantify human health improvements resulting from NIH-funded research, there are proxy measures. As one example, a study published in JAMA Health Forum found that NIH funding supported the development of 386 of 387 drugs approved by the Food and Drug Administration from 2010-19. Many of the approved drugs address the most pressing human health concerns of our time, including cancer, diabetes, cardiovascular disease, infectious diseases and neurological disorders such as Parkinson's disease.
Many other NIH-funded advancements represent what is now considered common knowledge, such as the relationship between cholesterol and cardiovascular health, or standard practice, such as screening newborns for serious diseases that may be treatable with early medical intervention. But each of these fundamental aspects of contemporary medicine had to first be discovered, tested and proved. They represent what NIH funding can do — and the type of paradigm-shifting advancements in medicine that are now very much at risk.
Consider the biotechnology industry as one such paradigm shift. In the 1970s, Stanley Cohen and Herbert Boyer were the first scientists to clone DNA and to transplant genes from one living organism to another. This work launched the biotechnology industry.
Two decades later, the NIH and the Department of Energy began a 13-year effort to sequence the human genome, including through university-based research grants. In 2003, the consortium of researchers produced a sequence accounting for 92% of the human genome. In 2022, a group of researchers primarily funded by the NIH's National Human Genome Research Institute produced a complete human genome sequence. This work paved the way for insights into inherited diseases, pharmacogenomics (how genetics affect the body's response to medications) and precision medicine.
NIH funding has also led to major breakthroughs in cancer treatments. In 1948, Sidney Farber demonstrated the first use of a chemotherapy drug, aminopterin, to induce remission in children with acute leukemia. Before Farber's research, which was funded in part by the NIH, children with acute leukemia were unlikely to survive even five years.
Over the years that followed, other modes of cancer treatment such as immunotherapy emerged, first as novel areas of inquiry, followed by drug development and clinical trials. NIH funding supported, among others, the development of CAR T cell therapy, which genetically modifies a patients' own T-cells to fight cancer. CAR T cell therapy has improved outcomes for many patients with persistent blood cancers, and clinical trials are ongoing to discover other cancers that might be treatable with CAR T cell therapies.
For decades, scientists knew that breast cancer could run in families and hypothesized a genetic role. In the 1990s, teams of scientists — supported at least in part by NIH funding — tracked down the BRCA1 and BRCA2 genes responsible for inherited predispositions to breast and other cancers. Today, many people undergo testing for BRCA gene mutations to make informed decisions about prevention, screening and treatment.
These kinds of advancements, along with improvements in detection and screening, have meaningfully reduced cancer mortality rates. After hitting a smoking-related peak in 1991, U.S. mortality rates from all cancers dropped by 34% as of 2022, according to the American Cancer Society. For children with acute leukemias, who had effectively no long-term chance of survival just 75 years ago, the numbers are even more dramatic. The five-year survival rate is now approximately 90% for children with acute lymphocytic leukemia and between 65% and 70% for those with acute myelogenous leukemia.
These examples represent a fraction of the tremendous progress that has occurred through decades of compounding knowledge and research. Reductions in NIH funding now threaten similar breakthroughs that are the prerequisites to better care, better technology and better outcomes in the most common health concerns and diseases of our time.
It is not research alone that is threatened by NIH funding cuts. Researchers, too, face new uncertainties. We have heard firsthand the anxiety around building a research career in the current environment. Many young physician-scientists wonder whether it will be financially viable to build their own lab in the U.S., or to find jobs at research institutions that must tighten their belts. Many medical residents, fellows and junior faculty are considering leaving the U.S. to train and build careers elsewhere. Losing early-career researchers to other fields or countries would be a blow to talent for biomedical research institutions nationwide and weaken the country's ability to compete globally in the biomedical sector.
The effects of decreased NIH funding might not be immediately visible to most Americans, but as grant cancellations and delays mount, there will be a price. NIH funding produces incredible results. Cuts will set scientific research back and result in losses in quality of life and longevity for generations of Americans in years to come.
Euan Ashley is the chair of the Stanford University department of medicine and a professor of medicine and of genetics. He is the author of 'The Genome Odyssey: Medical Mysteries and the Incredible Quest to Solve Them.' Rachel Keranen is a writer in the Stanford department of medicine.
If it's in the news right now, the L.A. Times' Opinion section covers it. Sign up for our weekly opinion newsletter.
This story originally appeared in Los Angeles Times.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Columbia Agrees to $200 Million Fine to Settle Fight With Trump
Columbia Agrees to $200 Million Fine to Settle Fight With Trump

New York Times

timean hour ago

  • New York Times

Columbia Agrees to $200 Million Fine to Settle Fight With Trump

Columbia University will pay a $200 million fine to settle allegations from the Trump administration that it failed to do enough to stop the harassment of Jewish students, part of a sweeping deal reached on Wednesday to restore the university's federal research funding, according to a statement from the university. In exchange for the return of hundreds of millions in research grants, Columbia will also pledge to follow laws banning the consideration of race in admissions and hiring, and follow through on other commitments to reduce antisemitism and unrest on campus that it agreed to in March. The deal, which settles more than a half-dozen open civil rights investigations into the university, will be overseen by an independent monitor agreed to by both sides who will report to the government on its progress every six months. The deal is a significant milestone in the Trump administration's quest to bring elite universities to heel. Columbia is the first university to reach a negotiated settlement over antisemitism claims. Harvard, which has sued the administration over funding cuts, is also negotiating for restoration of its federal money. The expectation is that the Columbia settlement will provide a template for future deals. The federal government is agreeing to restore grants terminated by the National Institutes of Health and the Department of Health and Human Services, and allow money to start flowing again to grants that had been frozen but were not canceled. Columbia can also compete on equal footing for new grants. The university will pay the $200 million in three installments over three years. The loss of funding for scientific research had become an urgent matter for Columbia, imperiling decades of work and bringing Columbia to the 'tipping point' of preserving its research excellence, the university said. Want all of The Times? Subscribe.

What to know about Parkinson's disease following Ozzy Osbourne's death

time6 hours ago

What to know about Parkinson's disease following Ozzy Osbourne's death

Ozzy Osbourne, lead singer of the legendary heavy metal rock band Black Sabbath, died this week at age 76. Although Osbourne's cause of death hasn't yet been publicly released, he revealed in an exclusive interview with " Good Morning America" in 2020 that he had been diagnosed with Parkinson's disease in February of the previous year. "There's so many different types of Parkinson's. It's not a death sentence by any stretch of the imagination but it does affect certain nerves in your body," Osbourne's wife, Sharon, said during the interview. "And it's like you have a good day, a good day, and then a really bad day." Here's what you need to know about Parkinson's, including what are the symptoms, how it's diagnosed and what treatments are available. What is Parkinson's disease? Parkinson's is a neurodegenerative disorder characterized by the weakening of nerve cells, which become damaged and die, according to the National Institute of Neurological Disorders and Stroke (NINDS). The most significant loss of neurons occurs in an area near the base of the brain called the substantia nigra, NINDS said. The neurons in the substantia nigra produce dopamine, which is a neurotransmitter that plays a vital role in controlling movement. "As we grow older, all of us lose dopamine but the people who develop Parkinson's disease lose it faster," Dr. Osama Abu-Hadid, a neurologist specializing in movement disorders at New Jersey's Hackensack Meridian Neuroscience Institute at Hackensack University Medical Center, told ABC News. Parkinson's affects more than 1.1 million people in the U.S., according to the Parkinson's Foundation. That figure is expected to reach 1.2 million by 2030. "Generally, neurodegenerative diseases such as Alzheimer's and Parkinson's disease have been on the increase because people are living longer," Abu-Hadid said. There currently are no specific tests to diagnose Parkinson's disease. The diagnosis is clinical based on a physician's review of a patient's medical history and by performing a physical examination. What are the symptoms of Parkinson's disease? Progression of Parkinson's disease symptoms typically occurs slowly over several years and can vary from person to person, according to the Parkinson's Foundation. Typically, symptoms begin on one side of the body. While Parkinson's will eventually affect both sides of the body, one side will generally exhibit more severe symptoms than the other, according to NINDS. Symptoms of Parkinson's can include tremors, muscle stiffness, slowing of spontaneous movement, and problems with gait and balance. Patients may also experience difficulty chewing and swallowing or changes in speech. Some patients can also develop non-motor symptoms, including constipation, hallucinations, depression, loss of smell and sleep problems, Abu-Hadid said. What Parkinson's disease treatments are available? Currently, there is no cure for Parkinson's, but physical therapy can help slow progression of the disease and a healthy diet can promote overall well-being, according to Abu-Hadid. However, there are medications that may improve some Parkinson's symptoms. These include drugs that increase the level of dopamine in the brain, drugs that interact with other neurotransmitters to help ease some symptoms, and medications that can help control the non-motor symptoms, according to NINDS. If medications aren't working, "procedural options include deep brain stimulation, which is an electrode, or electrodes, that are placed in the brain by a neurosurgeon, and then a physician like myself programs the electrodes to give electricity in a certain way," Abu-Hadid said. The electrodes can stimulate the brain and help block signals that cause the motor symptoms of Parkinson's, according to NINDS.

U.S. nuclear and health agencies hit in Microsoft SharePoint breach
U.S. nuclear and health agencies hit in Microsoft SharePoint breach

Washington Post

time8 hours ago

  • Washington Post

U.S. nuclear and health agencies hit in Microsoft SharePoint breach

The National Institutes of Health and the federal agency responsible for securing the nation's nuclear weapons were among the victims in a global breach of Microsoft server software over the weekend, according to agency officials and other people familiar with the matter. The NIH breach, which has not been previously reported, involved at least one Microsoft SharePoint server system, said Andrew Nixon, a spokesman for the Department of Health and Human Services, and its scope and severity are being investigated.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store